Search the Newsroom
Filter By
News Type
Showing 21 - 30 of 38 results
Children with Food Protein-Induced Enterocolitis More Likely to Have Other Allergies
CHOP researchers find the rare food allergy is linked with other allergies but does not cause them
CHOP Researchers Win Science Center Award to Develop AML Treatment
The $200,000 award will fund research to develop a novel therapeutic that ignites the immune system and could act as a stand-alone treatment, as well as boost the effectiveness of existing immunotherapies.
AML Immunotherapy Trial Opens
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
Dr. Jonathan Spergel Discusses Skin Patch Study with MD Magazine
Chief of CHOP’s Allergy Program talks about how a skin patch can help patients with eosinophilic esophagitis.
Skin Patch Shows Promise for Children with Milk-induced Eosinophilic Esophagitis
A new study finds a skin patch may be useful in treating children with eosinophilic esophagitis (EoE) triggered by milk.
Humanized CD19: CAR-T Immunotherapy for First Relapse of ALL in Down Syndrome Patient
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.
CHOP Scientists Report How Some Cancer Cells Develop Resistance to CAR T-cell Therapy
CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.
No More Kids with Cancer Awards $220,000 to CHOP
The $220,000 award will be directed to a Phase I clinical trial that will investigate the effectiveness of CAR T-cell therapy to treat AML.
Advancing the Field of Cell Therapy
A bone marrow transplant saved Kaleo’s life. Today, he’s a dancing machine. His success story is an example of CHOP’s expertise in the field of cellular therapy.
Shortened Inpatient Stays Benefit Certain Leukemia and Lymphoma Patients
Thanks to a recent initiative at CHOP, patients newly diagnosed with B-cell and T-cell ALL, and lymphoblastic lymphoma, now go home on average 9 days after diagnosis — that's 3 weeks sooner than previous stays.